Nazmul Hoque, MD
Gastroenterology · Newport, ORNPI 1740280429
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.3% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $683 and has fallen 53.6% since, to $317 in 2025.
Across 70 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$262
- Johnson & Johnson$194
- Shionogi Inc$119
- Sanofi$91
- Novo Nordisk$90
- Astellas Pharma US Inc$86
- plus $514 from 16 others
What the payments were for
- Food & beverage$1,25292%
- Education$1058%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $262 |
| Johnson & Johnson(2 entities) | 8 | $194 |
| Shionogi Inc | 7 | $119 |
| Sanofi | 4 | $91 |
| Novo Nordisk | 4 | $90 |
| Astellas Pharma US Inc | 5 | $86 |
| Amgen(2 entities) | 4 | $78 |
| GSK | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Pfizer | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 3 | $37 |
| Lilly USA, LLC | 2 | $36 |
| Bayer | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Boehringer Ingelheim | 1 | $34 |
| Exact Sciences | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Philips North America LLC | 1 | $17 |
| Merck | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $13 |
| UCB, Inc. | 1 | $12 |
How this compares
$1,357 in reported general payments places this provider in the 75th percentile of 220 gastroenterology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 91 | $69,181 |
| CreonLipase/Protease/Amylase | 25 | $55,400 |
| JanuviaSitagliptin Phosphate | 49 | $34,486 |
| EliquisApixaban | 23 | $19,102 |
| Budesonide DrBudesonide | 74 | $15,918 |
| XareltoRivaroxaban | 25 | $14,027 |
| JardianceEmpagliflozin | 11 | $13,765 |
| Spiriva HandihalerTiotropium Bromide | 12 | $10,605 |
| RybelsusSemaglutide | 11 | $10,349 |
| GemtesaVibegron | 17 | $8,277 |
| Omeprazole | 452 | $7,814 |
| OxycontinOxycodone Hcl | 13 | $7,628 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $6,962 |
| Sucralfate | 54 | $5,866 |
| MyrbetriqMirabegron | 11 | $5,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $262 | $124,580116 claims |
| MerckJanuvia, Janumet Xr | $16 | $41,44861 claims |
| PfizerEliquis | $40 | $19,10223 claims |
| Johnson & JohnsonXarelto | $194 | $14,02725 claims |
| Boehringer IngelheimJardiance | $34 | $13,76511 claims |
| Novo NordiskRybelsus | $90 | $10,34911 claims |
| Astellas Pharma US IncMyrbetriq | $86 | $5,39411 claims |
| GSKBreo Ellipta | $59 | $5,26313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 220 gastroenterology providers in Oregon.
Other gastroenterology in Newport
- Donald LumPortland$320K
- Rebecca MatroPortland$154K
- Ian HolmesPortland$102K
- Amy ZhuPortland$72K
- Gregory CotePortland$58K
- Emily JonicaPortland$49K
- Rebecca FauselPortland$29K
- Anil SharmaPortland$14K
- Jennifer RodriguezGresham$11K
- Harry BrayPortland$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.